Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory bowel disease characterised by continuous inflammation of the colonic mucosa, beginning in the rectum and extending proximally to varying degrees. Unlike Crohn’s disease, inflammation in ulcerative colitis is largely confined to the mucosa and submucosa, yet can produce profound local and systemic effects. Understanding the pathophysiology of ulcerative colitis explains why disease severity is driven by surface area involvement rather than depth, why bleeding is a prominent feature, and why complications may arise despite inflammation being relatively superficial.
What You Need to Know
Ulcerative colitis is a chronic inflammatory condition in which immune regulation within the colonic mucosa becomes dysregulated, leading to persistent and inappropriate inflammatory activation. The colon plays a key role in barrier integrity, immune tolerance, and absorption of water and electrolytes. In ulcerative colitis, this finely balanced system fails, and inflammation becomes continuous rather than self-limiting, targeting the mucosal layer of the colon.
Ongoing inflammation disrupts epithelial integrity by damaging surface cells and tight junctions, increasing permeability and impairing the mucosa’s ability to heal effectively. As epithelial injury persists, the colon loses its capacity to regulate fluid and electrolyte movement, and inflammatory mediators amplify local and systemic immune activation. These mechanisms explain why even limited mucosal disease can produce significant symptoms and physiological disturbance.
Several linked processes drive the clinical features of ulcerative colitis:
immune-mediated injury confined to the colonic mucosa leading to epithelial disruption and ulceration
impaired water and electrolyte absorption due to loss of functional mucosal surface
sustained inflammatory signalling that contributes to bleeding, diarrhoea, and systemic effects
Because inflammation is continuous and confined to the colon, symptoms such as diarrhoea and rectal bleeding often correlate with disease extent, but systemic consequences may develop even when disease appears anatomically limited. Ulcerative colitis therefore reflects a failure of mucosal immune regulation and barrier repair rather than episodic inflammation, with clinical impact driven by both local epithelial dysfunction and ongoing inflammatory burden.
Beyond the Basics
Loss of immune tolerance in the colonic mucosa
The colon contains a dense and metabolically active microbial population that normally coexists with the immune system in a regulated state of tolerance. This balance allows immune cells to ignore harmless luminal antigens while remaining responsive to true threats. In ulcerative colitis, this tolerance is lost. Immune cells mount a sustained inflammatory response against commensal bacteria and luminal antigens, and this response fails to down-regulate once initiated. Persistent cytokine release drives ongoing mucosal injury rather than resolution.
This loss of tolerance means inflammation is not triggered by a single pathogen or insult but is maintained by continuous antigen exposure within the colonic lumen. As a result, immune activation becomes self-sustaining and closely linked to barrier disruption and epithelial damage.
Continuous, surface-based inflammation
Inflammation in ulcerative colitis spreads in a continuous pattern along the colonic mucosa, without skip areas. This reflects the surface-based nature of immune activation, which remains confined to the mucosal layer rather than penetrating deeply through the bowel wall. Although inflammation is typically limited to the mucosa and submucosa, its continuous distribution results in extensive surface involvement.
Because the colon’s absorptive and barrier functions depend on an intact mucosal surface, widespread superficial inflammation produces significant functional impairment. Loss of absorptive capacity and barrier integrity occurs even in the absence of transmural disease, explaining why symptoms can be severe despite inflammation remaining relatively shallow.
Epithelial barrier breakdown and ulceration
Persistent inflammation damages epithelial cells and disrupts tight junctions that normally regulate permeability. As the barrier weakens, luminal antigens gain increased access to the immune system, further amplifying immune activation. Ulceration develops when epithelial injury exceeds the capacity for regeneration. These ulcers are typically shallow but extensive, reflecting surface loss rather than deep tissue destruction. This pattern explains the high risk of bleeding and protein loss seen in ulcerative colitis, even though the bowel wall remains structurally intact at deeper levels.
Impaired mucosal healing
Effective mucosal healing requires inflammatory signalling to subside so epithelial regeneration can stabilise the barrier. In ulcerative colitis, inflammation remains active during attempted repair. Newly generated epithelial cells are immature and fragile, forming a friable mucosa that breaks down easily. This unstable regeneration underpins the chronic and relapsing nature of the disease. Even when symptoms temporarily improve, incomplete healing leaves the mucosa vulnerable to rapid recurrence of inflammation and ulceration.
Vascular changes and bleeding
Inflammation within the colonic mucosa causes vasodilation and increases capillary fragility. Combined with epithelial ulceration, this leads to frequent bleeding from superficial vessels. Because injury is widespread rather than focal, bleeding is often persistent and low-grade rather than sudden or catastrophic. Chronic blood loss contributes to iron deficiency and fatigue, which may dominate the clinical picture even when diarrhoea is less prominent. These vascular changes are a direct consequence of mucosal inflammation rather than a separate bleeding disorder.
Fluid and electrolyte disturbance
The colon plays a central role in reclaiming water and electrolytes from luminal contents. Mucosal inflammation impairs this function by reducing absorptive capacity and increasing secretion driven by inflammatory mediators. The result is diarrhoea with loss of fluid and electrolytes. Ongoing losses contribute to dehydration, hypokalaemia, and systemic weakness, particularly during active disease. These disturbances reflect functional failure of the inflamed mucosa rather than excessive intake or primary renal dysfunction.
Systemic inflammatory effects
Cytokines released from the inflamed colonic mucosa enter the systemic circulation and drive extra-intestinal manifestations. Involvement of the skin, joints, eyes, and hepatobiliary system reflects shared immune activation rather than extension of intestinal disease beyond the gut. The likelihood of systemic features increases with the extent and duration of colonic inflammation, highlighting the colon as a source of ongoing inflammatory signalling that affects the whole body.
Risk of colonic dysplasia and malignancy
Chronic inflammation accelerates epithelial turnover and increases the risk of DNA replication errors. Over time, this cumulative injury raises the risk of colonic dysplasia and colorectal cancer. Risk correlates with duration and extent of disease rather than symptom severity at any given time. This long-term consequence reflects sustained inflammatory exposure rather than episodic disease activity, reinforcing the importance of maintaining durable mucosal healing to reduce cumulative risk.
Clinical Connections
Ulcerative colitis typically presents with bloody diarrhoea, urgency, tenesmus, and abdominal discomfort, reflecting active inflammation of the colonic mucosa. Symptom intensity often fluctuates over time, corresponding to changes in inflammatory activity rather than stepwise structural progression of disease. During active inflammation, superficial ulceration and capillary fragility lead to bleeding, while impaired water and electrolyte absorption produces diarrhoea and urgency. When inflammation settles, symptoms may improve rapidly, even though the underlying susceptibility to relapse remains.
Several clinical features directly reflect the underlying mucosal and inflammatory pathology:
bloody diarrhoea driven by superficial ulceration and fragile mucosal vasculature
urgency and tenesmus caused by rectal inflammation and reduced reservoir function
fatigue and anaemia resulting from chronic inflammation and ongoing blood loss
Management is therefore directed at suppressing mucosal inflammation and restoring barrier integrity rather than responding only to symptoms as they arise. Symptom control without adequate suppression of inflammation allows ongoing epithelial injury and immune activation, increasing the risk of relapse and cumulative damage. Achieving and maintaining mucosal healing reduces bleeding, improves absorptive function, and limits systemic inflammatory burden.
Long-term strategies focus on sustained remission rather than episodic treatment of flares. Persistent low-grade inflammation accelerates epithelial turnover and increases the risk of dysplasia and colorectal cancer over time. By maintaining immune control at the mucosal surface, treatment aims to prevent cumulative tissue injury, reduce systemic complications, and lower long-term malignancy risk, even when symptoms are minimal or absent.
Concept Check
Why does ulcerative colitis involve continuous rather than patchy inflammation?
How does superficial mucosal inflammation cause significant bleeding?
Why is diarrhoea a prominent feature even without deep tissue injury?
How does persistent inflammation impair mucosal healing?
Why does long-standing ulcerative colitis increase colorectal cancer risk?